Funds Holding Seattle Genetics, Inc.

 
Fund Quotes for Funds Holding Seattle Genetics, Inc. top ^
  • Holdings: Amgen Inc , Eli Lilly and Co , Roche Holding AG Dividend Right Cert. , Seattle Genetics Inc , Biogen Idec Inc ,
  • Category: Large Growth
  • Morningstar Rating: 5 Stars
Sign-up for pogrx investment picks

 
Stock Quotes for Seattle Genetics, Inc. top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Mid Growth
  • Stock Type: Speculative Growth
  • Morningstar Rating: 3 Stars
Sign-up for sgen investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Mid Growth
  • Stock Type: Speculative Growth
  • Morningstar Rating: 3 Stars
Sign-up for sgen investment picks

 
News Articles for Seattle Genetics, Inc. top ^
2014/12/7
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.
Sign-up for Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting investment picks
2014/12/6
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from two ongoing phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA December 6-9, 2014.
Sign-up for Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting investment picks
2014/12/6
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
2014/12/8
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted multiple ADCETRIS (brentuximab vedotin) data presentations in frontline and salvage Hodgkin lymphoma (HL) at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9, 2014.
Sign-up for Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting investment picks
2015/1/6
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Sign-up for Seattle Genetics to Present at the J.P. Morgan Healthcare Conference investment picks
2014/12/18
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML). The trial will also evaluate SGN-CD33A in the consolidation setting for AML, both in combination with cytarabine and as a single-agent maintenance regimen.
Sign-up for Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia investment picks
2015/1/12
Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials.
Sign-up for Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies investment picks
2015/1/21
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets.
Sign-up for Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015 investment picks
2015/2/5
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Sign-up for Seattle Genetics to Present at Leerink Global Healthcare Conference investment picks
2015/2/18
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse.
Sign-up for Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse investment picks
2015/2/17
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1 clinical trial of SEA-CD40 for multiple types of advanced solid tumors.
Sign-up for Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors investment picks
2015/2/10
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December 31, 2014.
Sign-up for Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Funds Holding Seattle Genetics, Inc.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Funds Holding Sears Canada Inc.  |  Next: Funds Holding Secom Co., Ltd.